The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Predicting IDH mutation status in grade II gliomas using amide proton transfer‐weighted (APTw) MRI
Open accessAbstract
Purpose: To assess the amide proton transfer‐weighted (APTw) MRI features of isocitrate dehydrogenase (IDH)‐wildtype and IDH‐mutant grade II gliomas and to test the hypothesis that the APTw signal is a surrogate imaging marker for identifying IDH mutation status preoperatively. Methods: Twenty‐seven patients with pathologically confirmed low‐grade glioma, who were previously scanned at 3T, were retrospectively analyzed. The Mann‐Whitney test was used to evaluate relationships between APTw intensities for IDH‐mutant and IDH‐wildtype groups, and receiver operator characteristic (ROC) analysis was used to assess the diagnostic performance of APTw. Results: Based on histopathology and molecular analysis, seven cases were diagnosed as IDH‐wildtype grade II gliomas and 20 cases as IDH‐mutant grade II gliomas. The maximum and minimum APTw values, based on multiple regions of interest, as well as the whole‐tumor histogram‐based mean and 50th percentile APTw values, were significantly higher in the IDH‐wildtype gliomas than in the IDH‐mutant groups. This corresponded to the areas under the ROC curves of 0.89, 0.76, 0.75, and 0.75, respectively, for the prediction of the IDH mutation status. Conclusion: IDH‐wildtype lesions typically were associated with relatively high APTw signal intensities as compared with IDH‐mutant lesions. The APTw signal could be a valuable imaging biomarker by which to identify IDH1 mutation status in grade II gliomas. Magn Reson Med 78:1100–1109, 2017. © 2017 International Society for Magnetic Resonance in Medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
IDH1 and IDH2 mutations in gliomas
Cohen, A. L., Holmen, S. L., & Colman, H. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0345-4 · Cited by 629
Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome
Reitman, Z. J., Jin, G., Karoly, E. D., Spasojevic, I., Yang, J., Kinzler, K. W., He, Y., Bigner, D. D., Vogelstein, B., & Yan, H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019393108 · Cited by 449 · cited 1×
“Because IDH geneencoded enzymes are closely involved in the energyproducing Krebs cycle as catalytic isozymes, mutations in IDH genes may cause widespread disturbances of cellular metabolism, including alteration of amino acid concentrations and enzymatic activity (7,8), and raise global DNA hypermethylation and globa…”
BackgroundAndronesi, O. C., Kim, G. S., Gerstner, E., Batchelor, T., Tzika, A. A., Fantin, V. R., Vander Heiden, M. G., & Sorensen, A. G. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002693 · Cited by 438
Pope, W. B., Prins, R. M., Albert Thomas, M., Nagarajan, R., Yen, K. E., Bittinger, M. A., Salamon, N., Chou, A. P., Yong, W. H., Soto, H., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0737-8 · Cited by 318
Isocitrate dehydrogenase-1 mutations: A fundamentally new understanding of diffuse glioma?
Kloosterhof, N. K., Bralten, L. B., Dubbink, H. J., French, P. J., & van den Bent, M. J. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70053-x · Cited by 222
Cited by
Pros and cons of ultra-high-field MRI/MRS for human application
Ladd, M. E., Bachert, P., Meyerspeer, M., Moser, E., Nagel, A. M., Norris, D. G., Schmitter, S., Speck, O., Straub, S., & Zaiss, M. (2018) · Progress in Nuclear Magnetic Resonance Spectroscopy · doi:10.1016/j.pnmrs.2018.06.001 · Cited by 544
APT‐weighted MRI: Techniques, current neuro applications, and challenging issues
Zhou, J., Heo, H., Knutsson, L., van Zijl, P. C. M., & Jiang, S. (2019) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.26645 · Cited by 345
Self-citationPseudoprogression of brain tumors
Thust, S. C., van den Bent, M. J., & Smits, M. (2018) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.26171 · Cited by 304
Metadata
- Authors
- Jiang, S., Zou, T., Eberhart, C. G., Villalobos, M. A. V., Heo, H., Zhang, Y., Wang, Y., Wang, X., Yu, H., Du, Y., van Zijl, P. C. M., Wen, Z., & Zhou, J.
- Venue
- Magnetic Resonance in Medicine
- Publisher
- Wiley
- Published
- 2017-07-16
- Volume
- 78
- Issue
- 3
- Pages
- 1100-1109
- ISSN
- 0740-3194 (ISSN-L)
- 1522-2594
- OpenAlex
- W2734807975
- Cited by
- 170
- References
- 8
- FWCI
- 7.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Predicting IDH mutation status in grade II gliomas using amide proton transfer‐weighted (APTw) MRI. https://app.cochat.ai/papers/10.1002/mrm.26820
- The paper
- Jiang, S., Zou, T., Eberhart, C. G., Villalobos, M. A. V., Heo, H., Zhang, Y., Wang, Y., Wang, X., Yu, H., Du, Y., van Zijl, P. C. M., Wen, Z., & Zhou, J. (2017). Predicting IDH mutation status in grade II gliomas using amide proton transfer‐weighted (APTw) MRI. Magnetic Resonance in Medicine. https://doi.org/10.1002/mrm.26820
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.